Episode

Ep. 181: Advancements in CIDP Treatment

Podcast
eanCast: Weekly Neurology
Published
Dec 28, 2025
Duration seconds
1975
Processing state
not_requested
Canonical source
https://eancast.podigee.io/181-ep-181-advancements-in-cidp-treatment
Audio
https://audio.podigee-cdn.net/2275474-m-db72fefecf88301d8aaf2a72f23c87a1.mp3?source=feed
JSON
/v1/public/podcasts/eancast-weekly-neurology-5497158/episodes/ep-181-advancements-in-cidp-treatment
Markdown
/podcast/eancast-weekly-neurology-5497158/ep-181-advancements-in-cidp-treatment.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/eancast-weekly-neurology-5497158/episodes/ep-181-advancements-in-cidp-treatment/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/eancast-weekly-neurology-5497158/ep-181-advancements-in-cidp-treatment.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Moderator: Rob Hadden (London, United Kingdom) Guest: Claudia Sommer (Würzburg, Germany) In this episode, Rob Hadden and Claudia Sommer discuss ongoing challenges in treating CIDP. While most patients benefit from current therapies, some remain treatment-refractory, driving the need for innovation. They highlight emerging response definitions, promising FcRn and complement inhibitors, and the importance of individualized care and serum biomarkers for improving patient outcomes. This episode has been supported by an educational grant from argenx. The programme has not been influenced in any way by its supporter.